SSI-4 is under clinical development for hepatocellular carcinoma [3], and in our study demonstrated potent anti-leukemic effects in vitro and in vivo on roughly half of AML samples and models tested while showing no general or hematopoietic toxicities. Here, SOCS6 is linked to acute myeloid leukemia.